

# Contents

## CHAPTER 1

### **A New Perspective for Drug Delivery Research**

R.L. JULIANO . . . . .	1
A. Promises Realized: A Recent History of Controlled Drug Delivery . .	1
I. Sustained Delivery Systems: A Clinical and Commercial Success	1
1. Implantable Systems . . . . .	2
2. Transdermal Systems . . . . .	2
II. Microparticulate Delivery Systems . . . . .	3
1. Solving Old Problems . . . . .	3
2. Clinical Evaluation . . . . .	4
B. The Opening Door: Molecular Biology Generates New Opportunities and Challenges for Drug Delivery Research : . . . . .	5
I. Using the Body's Own Pharmaceuticals . . . . .	5
II. Endocrine Vs Paracrine: A Drug Targeting Problem . . . . .	5
C. An Overview of this Volume: Building on the Past and Looking Toward the Future . . . . .	6
D. Drug Targeting Research in the Twenty-First Century: A New Perspective . . . . .	7
References . . . . .	8

## CHAPTER 2

### **Internalization and Sorting of Macromolecules: Endocytosis**

T.E. MCGRAW and F.R. MAXFIELD. With 3 Figures . . . . .	11
A. Introduction . . . . .	11
B. Pathways of Endocytosis in Nonpolarized Cells . . . . .	13
I. Endosomes . . . . .	15
II. Properties of Endosomes . . . . .	17
1. Acidification . . . . .	17
2. Endosome Fusion and Sorting . . . . .	20
3. Maturation of Endosomes . . . . .	23
C. Molecular Basis of Endocytosis . . . . .	24

I. Internalization .....	24
1. Required Receptor Sequences .....	24
2. Clathrin-Coated Pit Clustering Proteins .....	28
3. Formation of Endocytic Vesicles .....	28
II. Intracellular Routing .....	29
D. Noncoated Pit Internalization .....	31
E. Endocytosis in Polarized Cells .....	32
F. Summary .....	34
References .....	34

## CHAPTER 3

### **Transport of Macromolecules Across the Capillary Endothelium**

K.L. AUDUS and R.T. BORCHARDT. With 3 Figures .....	43
A. Introduction .....	43
B. Pathways for the Passage of Macromolecules Across Capillary Endothelium .....	43
I. Capillary Endothelium .....	43
II. Fenestrations .....	45
III. Large Pores .....	45
IV. Intercellular Junctions .....	46
V. Endocytosis and Phagocytosis .....	46
C. The Blood-Brain Barrier .....	48
D. Experimental Model Systems .....	49
I. Brain Perfusion Model .....	50
II. Isolated Capillaries .....	50
III. Tissue Culture Systems .....	51
E. Applications of Tissue Culture Models in the Study of Capillary Endothelial Cell Transport of Macromolecules .....	53
I. Kinetics of Marker Molecules .....	53
1. Lucifer Yellow .....	54
2. Lectins .....	54
II. Large Peptides .....	55
1. Transferrin .....	55
2. Insulin and Insulin-Like Growth Factor .....	56
3. Atrial Natriuretic Factor .....	57
4. Modified Albumins .....	57
III. Small Peptides .....	58
IV. Regulation of the Permeability of Capillary Endothelium .....	59
1. Astrocytes .....	59
2. Vasoactive Peptides .....	61
F. Summary .....	63
References .....	64

## CHAPTER 4

**Pharmacokinetics of Drug Targeting:****Specific Implications for Targeting via Prodrugs**

V.J. STELLA and A.S. KEARNEY. With 18 Figures .....	71
A. Introduction .....	71
B. Pharmacokinetic Models and Drug Targeting .....	72
I. Defining Drug Targeting .....	72
II. Testing Targeting Hypotheses Using Classical or Compartmental Pharmacokinetic Models .....	73
III. Testing Targeting Hypotheses Using Physiological Pharmacokinetic Models .....	78
1. Perfusion Models .....	78
2. Trafficking and Cellular Uptake Limitations .....	81
3. Specific Examples of Models Used to Evaluate and Predict Targeting Strategies .....	82
C. Prodrug-Mediated Targeted Drug Delivery .....	85
I. Prodrugs in General .....	85
II. Site-Specific Drug Delivery via Prodrugs .....	87
1. Indirect Drug Targeting via Prodrugs .....	88
2. Direct Drug Targeting via Prodrugs .....	93
References .....	100

## CHAPTER 5

**Soluble Polymers as Targetable Drug Carriers**

N.L. KRINICK and J. KOPEČEK. With 13 Figures .....	105
A. Introduction .....	105
B. Consequences of Drug Binding to Macromolecular Carriers: Cellular Level .....	106
I. Pinocytosis .....	106
1. Receptor-Mediated Endocytosis .....	108
II. Endosomes .....	111
III. Lysosomes .....	113
C. Fate of Macromolecular Carriers In Vivo .....	116
I. Principles of Biodegradability .....	117
II. Influence of Substitution on the Degradability of Natural Polymers .....	118
1. Polysaccharides .....	118
2. Polyamino Acids .....	119
III. Elimination of Macromolecular Carriers from the Organism .....	121
1. Structural Factors Influencing the Fate of Macromolecules ..	122
D. Release of Drugs .....	124
I. Release of Drugs by Hydrolysis .....	124

II. Disulfide Spacers . . . . .	125
III. Release of Drugs by Enzymes . . . . .	125
1. Release of Drug Models from HPMA Copolymers by Chymotrypsin . . . . .	126
2. Cleavage by Lysosomal Enzymes . . . . .	128
IV. Relationship Between Susceptibility to Enzymatically Catalyzed Hydrolysis and Biological Activity . . . . .	131
E. Targeting . . . . .	134
I. Principles of Targeting . . . . .	134
II. Obstacles to Targeted Drug Delivery . . . . .	135
1. Multidrug Resistance . . . . .	137
III. Targeting Lysosomes with Carbohydrate Moieties . . . . .	137
1. Asialoglycoproteins . . . . .	138
2. Lysosomal Hydrolases . . . . .	138
3. Glycoconjugates . . . . .	139
4. Synthetic and Natural Polymers . . . . .	140
IV. Antibodies . . . . .	143
1. Antibody-Drug Conjugates . . . . .	143
2. Antibody-Synthetic Polymer-Drug Conjugates . . . . .	149
3. Antibody-Natural Polymer-Drug Conjugates . . . . .	152
V. Hormones . . . . .	154
VI. Other Targeting Systems . . . . .	155
F. Photosensitization: Activation by Light . . . . .	156
I. Photodynamic Therapy . . . . .	157
1. Double Targeting . . . . .	158
2. Uptake of Photosensitizer Conjugates . . . . .	160
G. Decreased Toxicity and Immunogenicity of Drug-Polymer Conjugates . . . . .	161
I. Toxicity of Drug-Polymer Conjugates . . . . .	161
II. Immunogenicity of Polymer-Drug Conjugates . . . . .	162
H. Soluble Polymers for Site Specific Oral Drug Delivery . . . . .	163
I. Enzyme Controlled Site Specific Drug Release . . . . .	163
II. Bioadhesion of Polymeric Carriers . . . . .	164
III. Two Fold Specificity in Oral Drug Delivery . . . . .	165
I. Concluding Remarks . . . . .	166
References . . . . .	166

## CHAPTER 6

### Systemic Delivery of Pharmacologically Active Molecules Across the Skin

Y.W. CHIEN. With 33 Figures . . . . .	181
A. Biomedical Logic of Transdermal Drug Delivery . . . . .	181
I. Introduction . . . . .	181
II. The Skin Site for Percutaneous or Transdermal Drug Delivery . . . . .	182
III. Mechanisms and Kinetics of TDD . . . . .	184

B. Historic Development of TDD .....	187
C. Transdermal Delivery of Pharmacologically Active Organic Molecules .....	191
I. Nitroglycerin-Releasing TDD System .....	193
1. Membrane Permeation-Controlled Drug Delivery .....	193
2. Matrix Diffusion-Controlled Drug Delivery .....	196
3. Interfacial Partitioning-Controlled Drug Delivery .....	198
II. Scopolamine-Releasing TDD System .....	201
III. Clonidine-Releasing TDD System .....	201
IV. Estradiol-Releasing TDD System .....	202
V. Determination of TDD Kinetics .....	205
1. In Vitro Drug Release Kinetics .....	206
2. In Vitro Transdermal Permeation Kinetics .....	208
3. In Vivo Transdermal Permeation Kinetics .....	210
4. In Vitro and In Vivo Correlations of Transdermal Permeation Kinetics .....	213
VI. Optimization of Transdermal Controlled Drug Delivery .....	214
D. Transdermal Delivery of Pharmacologically Active Peptide/Protein Molecules .....	217
E. Conclusion .....	226
References .....	227

## CHAPTER 7

### Chemical Delivery Systems

N. BODOR and M.E. BREWSTER. With 40 Figures .....	231
A. Introduction .....	231
B. Site and Stereospecific Drug Delivery to the Eye .....	231
C. Brain-Targeting Drug Delivery .....	236
I. Background .....	237
II. Dihyronicotinate CDSs .....	239
1. Brain-Targeting of Neurotransmitters and Amino Acids .....	241
2. Brain-Enhanced Delivery of Antiviral Agents .....	248
3. Application of the Brain-Targeting CDS to Estrogens .....	260
4. Conclusion .....	278
References .....	279

## CHAPTER 8

### In Vivo Behavior of Liposomes: Interactions with the Mononuclear Phagocyte System and Implications for Drug Targeting

G.L. SCHERPHOF .....	285
A. Introduction .....	285
B. Interactions with Body Fluids .....	286

C. Interactions with Cells . . . . .	288
D. Anatomical Barriers . . . . .	290
E. Factors Influencing Liposome Uptake by Cells . . . . .	293
I. Liposome Size . . . . .	295
II. Liposome Composition . . . . .	296
III. Cholesterol and Opsonization . . . . .	297
IV. Prolonged Circulation Time . . . . .	300
F. Surface Modification . . . . .	302
G. Intracellular Processing of Liposomes . . . . .	305
H. Implications for Drug Targeting . . . . .	307
I. Concluding Remarks . . . . .	312
References . . . . .	313

## CHAPTER 9

### **Antisense Oligonucleotides as Pharmacological Modulators of Gene Expression**

G. DEGOLS, J.-P. LEONETTI, and B. LEBLEU. With 2 Figures . . . . .	329
A. General Principles and Historical Background . . . . .	329
B. Artificial Control of Gene Expression by Synthetic Oligonucleotides: An Overview of Problems and Potential . . . . .	331
C. Oligonucleotide Chemistry and Modifications . . . . .	332
I. Modifications of the Phosphodiester Backbone . . . . .	332
1. Nonionic Oligonucleotides . . . . .	332
2. Isoelectric Oligonucleotides . . . . .	333
3. Phosphoramidate Oligonucleotides . . . . .	334
II. Modifications of the Sugar Moiety . . . . .	334
1. Sugar-Modified Oligonucleotides . . . . .	334
2. Oligoribonucleotide Analogues . . . . .	335
III. Functionalization of Oligonucleotide Ends . . . . .	336
D. Internalization Pathway of Antisense Oligonucleotides and Alternative Methods to Increased Cellular Uptake . . . . .	337
I. Mechanism of Uptake of Oligonucleotides in Cells . . . . .	337
II. Modifications of Oligonucleotides to Increase Cell Uptake . . . . .	338
E. Mechanism of Action of Antisense Oligonucleotides . . . . .	340
F. Biological Potential of Synthetic Oligonucleotides . . . . .	342
G. Prospectives of In Vivo Utilization of Antisense Oligonucleotides . . . . .	345
References . . . . .	348

<b>Subject Index</b> . . . . .	355
--------------------------------	-----